CRON
Cronos Group Inc.
CRON has a slight edge over LLY overall, supported by stronger fundamentals.
LLY
Eli Lilly and Company
LLY has slightly lower modeled downside risk, despite its lower overall score.
CRON Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
CRON's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CRON PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 3.8x | $0.62 | -82% |
| Forward | 17x | $3.41 | — |
| Fair | 18x | $2.82 | -17% |
| Current | 21x | $3.41 | — |
| Expensive | 40x | $6.32 | +85% |
Historical ranges are pointers, not guarantees.
CRON's PE is in its fair range at 21x. If earnings grow as analysts expect, today's price would be 17x next year's earnings.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over CRON in the historical PE scenario, which offers more potential upside but is not a forecast.
CRON Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect strong earnings and revenue growth for CRON, with profitability improving.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CRON Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.20 | +25% |
| Q3 2026 | $0.16 | +45% |
| Q2 2026 | $0.19 | +217% |
| Q1 2026 | $0.00 | -100% |
| Q4 2025 | -$0.02 | -118% |
| Q3 2025 | $0.11 | +$0.24 |
| Q2 2025 | $0.06 | +$0.21 |
| Q1 2025 | $0.14 | +$0.29 |
| Q4 2024 | $0.11 | +$0.30 |
CRON's earnings per share have fallen from their peak: $0.16 over the past year, against $2.12 in late 2019.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CRON on earnings, with more consistent year-over-year improvement.
CRON Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $63.5M | +75% |
| Q2 2026 | $53M | +58% |
| Q1 2026 | $45.2M | +40% |
| Q4 2025 | $44.5M | +47% |
| Q3 2025 | $36.3M | +6.1% |
| Q2 2025 | $33.5M | +21% |
| Q1 2025 | $32.3M | +28% |
| Q4 2024 | $30.3M | +27% |
CRON's revenue has grown year over year for 13 quarters in a row: $63M last quarter, up 75% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +16 points |
| Q2 2026 | 14% | +30 points |
| Q1 2026 | -4% | +8.6 points |
| Q4 2025 | -17% | +21 points |
| Q3 2025 | -1.4% | +97 points |
| Q2 2025 | -16% | +40 points |
| Q1 2025 | -13% | +51 points |
| Q4 2024 | -38% | +53 points |
CRON's operating margin was 14% last quarter, up 16 points from the same quarter a year ago, near the top of its range since 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CRON on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CRON on profitability, with a higher operating margin.
CRON Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $24.4M | +176% |
| Q2 2026 | $22.3M | +$23.3M |
| Q1 2026 | $9M | +$26.4M |
| Q4 2025 | $9.7M | +132% |
| Q3 2025 | $8.8M | +71% |
| Q2 2025 | -$1M | -200% |
| Q1 2025 | -$17.4M | -$13.4M |
| Q4 2024 | $4.2M | -73% |
CRON's free cash flow has turned positive again: $65M over the past year, against −$5M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CRON on cash flow, with more consistent year-over-year improvement.
CRON Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -4.3M shares |
| 1 year | -3.7% | -14.3M shares |
| 3 years | -2.7% | -10.4M shares |
| 5 years | -1.3% | -4.9M shares |
| Available history | +8.1% | +27.9M shares |
CRON has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $9.4M |
| Q2 2026 | $16.1M |
| Q1 2026 | $16.7M |
| Q4 2025 | $4.3M |
| Q3 2025 | $1.9M |
CRON spent $47M buying back its own shares over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CRON Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -27.0x | Net Cash |
| Q2 2026 | -82.1x | Net Cash |
CRON has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CRON Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.6 | Neutral |
| Stochastic | 62.5 | Neutral |
CRON's weekly RSI is 61 (neutral) and its Stochastic is 62 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CRON PE vs Healthcare Sector
| Metric | CRON | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 26x | 18% below |
| PE % | 54 | 29 | 25 pts above |
CRON has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CRON Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.33 | 2.4% above |
| 20 week MA | $3.17 | 7.6% above |
| 50 week MA | $2.87 | 19% above |
| 100 week MA | $2.50 | 36% above |
| 200 week MA | $2.31 | 48% above |
CRON is in an uptrend: it's above all five of its weekly moving averages, and 48% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
CRON Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.88 | $7.48 | +8.7% |
| 2021 | $7.48 | $4.26 | -43% |
| 2022 | $4.26 | $2.54 | -40% |
| 2023 | $2.54 | $2.09 | -18% |
| 2024 | $2.09 | $1.98 | -5.3% |
| 2025 | $1.98 | $2.66 | +34% |
| 2026 YTD | $2.66 | $3.41 | +28% |
CRON has finished lower in four of the last six years. It's up 28% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CRON on returns for 2026, with the stronger performance.